PharmiWeb.com - Global Pharma News & Resources

Clinical trials - Press Releases

Date Title Company
25-Mar-2021 Invite from Jim Polarine and Geeta Singh, Co-Chairs to join Pharmaceutical Microbiology West Coast Virtual Conference SMi Group
25-Mar-2021 Enterome Receives FDA IND Clearance for EO2463, an ‘OncoMimic’ based Immunotherapy Targeting Liquid Tumors Enterome
25-Mar-2021 MedVector Launches its Prime-Control Technology to Expand Subject Enrollment Beyond Clinical Trial Sites MedVector
25-Mar-2021 SignalChem Enters a Clinical Trial Collaboration with Merck to Evaluate the Effect of SLC-391 in Combination with KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer SignalChem
25-Mar-2021 Anaveon receives CTA approval to start a Phase I/II study to evaluate the safety, dosing and clinical activity of AVN419 in patients with solid tumors Anaveon
25-Mar-2021 Qlucore announces major new release (3.7) with ChIP-seq and Biomarker support Qlucore
25-Mar-2021 AZD1222 US Phase III primary analysis confirms safety and efficacy AstraZeneca
24-Mar-2021 Myovant Sciences and Pfizer Announce Positive Data From Phase 3 Liberty Randomized Withdrawal Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids Pfizer
24-Mar-2021 Pfizer Initiates Phase 1 Study of Novel Oral Antiviral Therapeutic Agent Against SARS-CoV-2 Pfizer
24-Mar-2021 TOT BIOPHARM Announces A Number of Key Anti-Tumor Drugs Have Entered the Pivotal Clinical Stage in 2020 TOT BIOPHARM
23-Mar-2021 TrialWire launches StudyBoost, the Clinical Trial Insurance Plan TrialWire
23-Mar-2021 RECORDATI RARE DISEASES: POSITIVE RESULTS FROM THE PHASE III LINC 4 STUDY PRESENTED TODAY AT THE ENDOCRINE SOCIETY’S ANNUAL MEETING REINFORCE THE EFFICACY AND SAFETY OF ISTURISA® (OSILODROSTAT) IN CUSHING’S DISEASE Recordati Rare Diseases
22-Mar-2021 AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis AstraZeneca
19-Mar-2021 Resistance-busting ICR drug enters clinical trial The Institute of Cancer Research, London
18-Mar-2021 Invite from Justin Mason-Home, Chair at SMi’s 5th Annual Highly Potent Active Pharmaceutical Ingredients 2021 SMi Group
18-Mar-2021 $15 million for development of innovative therapies for mental illness Department of Health Australia
18-Mar-2021 Gilead Sciences and Novo Nordisk expand NASH clinical collaboration Novo Nordisk
17-Mar-2021 Invitation from Michael Scherz and Naheed Mirza, Co-Chairs at Pain Therapeutics 2021 SMi Group
17-Mar-2021 Immutep Enters Second Collaboration with MSD For a New Randomised Phase IIB Trial in Head and Neck Cancer Immutep
17-Mar-2021 Lilly's Mirikizumab Helps Patients Achieve Clinical Remission and Improves Symptoms in Adults with Ulcerative Colitis in 12-Week Phase 3 Induction Study Lilly